Profile cover photo
Profile photo
Galectin Therapeutics
5 followers -
Combating Fatty Liver Disease & Liver Fibrosis
Combating Fatty Liver Disease & Liver Fibrosis

5 followers
About
Posts

Post has attachment
Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis - http://buff.ly/2djOlaV

Research to be presented at The Liver Meeting® 2016 demonstrates correlation of FibroScan and MRE as non-invasive tests to assess the progression of liver fibrosis and cirrhosis

Read More:
Add a comment...

Post has attachment
Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis

Read more: http://buff.ly/2dq1rro

Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled

Closed private placement financing for $1.5 million

Conference call to be held today at 5:30 p.m. (Eastern Time)

Read more: http://buff.ly/2cAUkeT
Add a comment...

Post has attachment
Galectin Therapeutics to Present TODAY at Rodman & Renshaw 18th Annual Global Investment Conference, view here:
Add a comment...

Post has attachment
Cracking the Enigma of Fatty Liver Disease - http://buff.ly/2bGdw8Y

Approved Pharmacologic Treatments for NAFLD, NASH, and Cirrhosis Are Desperately Needed
Add a comment...

Post has attachment

Post has attachment
Add a comment...

Post has attachment
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update - http://buff.ly/2axgRbr

Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September. Australian patent allowance strengthens global intellectual property franchise.
Add a comment...

Post has attachment
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis - http://buff.ly/2b0tSHG

"We are pleased that patient recruitment in our NASH-CX trial was completed ahead of our original expectations," said Peter G. Traber, M.D., Galectin's president, chief executive officer and chief medical officer.
Add a comment...

Post has attachment
Bret Jensen's latest article on Seeking Alpha, "Some Potential NASH Plays," includes Galectin Therapeutics (NASDAQ: GALT) as one the companies positioned to address the health risks associated with the growing problem of fatty liver disease.

Read the article here:
Add a comment...

Post has attachment
Fatty Liver is an Enormous Global Problem - http://buff.ly/29SaZY6

I often write about fatty liver disease, a problem that is gaining mainstream recognition as published earlier this year in Newsweek. It is easy to assume that this is a problem just in the U.S., but data are coming in that highlight it as a global problem, as published in a recent article (1) and an accompanying editorial(2) in the journal Hepatology.

Read the entire article:
Add a comment...
Wait while more posts are being loaded